Obesity Models for Preclinical Research

Significant progress is being made in the field of anti-obesity therapies as a result of a greater understanding of the biological mechanisms underlying obesity and the need for effective interventions. Protheragen uses a variety of animal and cell models to support preclinical research of anti-obesity therapies. Available models include but are not limited to:

In Vivo Obesity Models

In Vitro Cell Models

Precision in Every Drop: Expert Bioanalysis for Anti-Obesity Research

Bioanalysis is an important step in the development and validation of anti-obesity therapies to ensure safety and efficacy. We provide a variety of tests using animal and cell models to meet our clients' bioanalysis requirements for anti-obesity therapies. Our services include:

Biological Analysis of Macromolecular Drugs

At Protheragen, utilizing state-of-the-art laboratory facilities and an experienced team of experts, we are committed to providing critical and reliable information and data for every stage of anti-obesity drug development, from early discovery to preclinical trials. Our bioanalytical services for anti-obesity macromolecules include precise pharmacokinetics (PK) studies, pharmacodynamics (PD) studies, rigorous toxicity assessments, detailed immunogenicity testing, etc., ensuring the highest safety and efficacy standards to meet your unique preclinical research needs. Our commitment to accuracy, innovation, and regulatory compliance makes us a trusted partner in your journey to develop effective anti-obesity therapies.

Bioanalysis of Small Molecule Drugs

At Protheragen, our team of experts provides cutting-edge bioanalytical services for small molecule drugs using mass spectrometry (MS), high-performance liquid chromatography (HPLC) and other technologies. Our goal is not just to measure, but to comprehensively analyze the PK, PD and metabolic pathways of your potential therapeutic drugs, paving the way for the development of weight loss therapies. Our safe, effective and regulatory compliant analytical methods will ensure that you accelerate your drug development process.

• Bioanalytical Method Validation

  Before adopting any bioanalytical technique, we conduct rigorous validation to ensure accuracy, precision, sensitivity, and reproducibility. These validations follow regulatory guidelines and are performed through a series of experiments to determine the robustness of the method under different conditions and matrix types.

• PK Studies

  Our drug metabolism and pharmacokinetics (DMPK) studies are designed to reveal the absorption, distribution, metabolism, and excretion (ADME) of therapeutic drugs in model animals and their complex interactions over time. This analysis involves how model animals metabolize drugs after administration, identifying the enzymes and pathways involved, the half-life and bioavailability of drugs, etc. Detailed preclinical PK analysis is essential to determine the optimal dose and frequency to achieve the desired therapeutic effect while minimizing side effects. We use advanced analytical techniques such as MS and HPLC to accurately measure drug concentrations in biological samples such as serum over time to provide reference data for clinical research of drugs.

• PD Studies

  PD studies of anti-obesity drugs focus on analyzing the drug's mechanism of action, dose-response relationship, efficacy, and side effects on the body. We analyze how drugs interact with biological targets (such as receptors or enzymes) and their subsequent effects on metabolic pathways, appetite regulation, and energy expenditure. Anti-obesity drugs generally reduce fat absorption or increase fat oxidation by suppressing appetite, increasing satiety, or altering metabolism. We help clients evaluate the occurrence, duration, and intensity of these reactions in model animals and study the potential for adverse reactions.

• Immunogenicity Testing

  Immunogenicity testing of anti-obesity drugs involves evaluating the potential of these drugs to elicit an immune response in model animals, which may affect the safety and efficacy of the drug. We screen for the presence of anti-drug antibodies using techniques such as enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR), and further assays to determine their specificity, titer, and neutralizing capacity. In addition, we evaluate the impact of anti-drug antibodies on PK, PD, and efficacy using cell-based assays and animal models.

• Toxicity Assessments

  We use cell culture to conduct in vitro studies to determine the cytotoxicity of the drug and the potential to cause cell damage. Then we study its acute, subchronic, and chronic toxicity in animal models to determine the maximum tolerated dose (MTD), no observed adverse effect level (NOAEL), and lethal dose (LD₅₀). We monitor and analyze the weight loss of animals after administration, biochemical markers in the blood, histopathological examination of major organs, etc.

Workflow

Applications

• Identify and quantify metabolites produced during drug metabolism to optimize drug design and predict possible drug interactions.
• Compare the bioavailability and bioequivalence of drugs with different formulations or different administration methods.
• Using advanced bioanalytical techniques, researchers discover and validate new biomarkers associated with treatment outcomes to develop personalized medicine approaches.
• Measure changes in drug concentrations over time in plasma, blood, urine, or tissues to determine parameters such as half-life, bioavailability, and clearance.

Advantages

• We use analytical methods such as MS, chromatography, and advanced bioinformatics to ensure accurate and reliable bioanalytical data for our clients.
• Our services cover the full range of bioanalytical needs for anti-obesity therapeutics, from biomarker discovery and quantification to PK, PD, and immunogenicity assessments.
• We adhere to strict regulatory guidelines to ensure that all bioanalytical studies and methods meet industry standards.
• We recognize that every drug development program is unique. Therefore, we provide customized bioanalytical solutions to meet your specific needs, from custom assay development to professional data interpretation.

Our Services

Addressing the multifaceted challenges of obesity requires a comprehensive range of services to meet research needs, and our dedicated team is committed to helping clients address obesity. Our services start with analyzing the causes of obesity to personalized weight management, ensuring a personalized solution tailored to the client's specific circumstances.

Publication Data

Frequently Asked Questions

What analytical techniques do you use?

Techniques commonly employed include but are not limited to liquid chromatography with tandem mass spectrometry (LC-MS-MS), ELISA, polymerase chain reaction (PCR), western blotting, and flow cytometry.

What type of sample matrices can you handle?

We hand a variety of sample matrices including blood, plasma, urine, tissue homogenates, and other biological fluids. Our extensive experience ensures that we effectively process and analyze these samples to generate high-quality data.

Protheragen has a place in the development of anti-obesity therapies, providing the development services of small molecule drugs, gene therapy, cell therapy, antibody therapy, etc. Our advanced preclinical research provides you with comprehensive and accurate efficacy determination and safety assessment, ensuring that you confidently convert experimental data into clinical success. Please feel free to contact us to transform innovative ideas into breakthrough therapies, bringing a healthier future to countless people fighting obesity.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Obesity Models
• Pharmacodynamic Study of Anti-Obesity Therapeutics
• Pharmacokinetic Study of Anti-Obesity Therapeutics
• Safety Assessment of Anti-Obesity Therapeutics